Merck Q4 ’18 Earnings Update

Merck held its Q4 ‘18 earnings call and briefly discussed its diabetes portfolio. Of note, Merck’s earnings press release highlighted the recent in-licensing of NGM313, renamed MK-3655 (monoclonal antibody agonist of the β-Klotho/FGFR1c receptor), which is being evaluated in T2DM and NASH. Additionally, senior management announced that the company will hold an investor event on June 20, 2019 to provide an update on Merck’s strategic progress and its plans for the future. Below are highlights from the call.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.